Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1Breast 1

Conditions

Melanoma 9Neoplasm Metastasis 3Urinary Bladder Neoplasms 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

pembrolizumab 12Nivolumab 10cemiplimab 5avelumab 5Ipilimumab 5atezolizumab 4poly ICLC 3fludarabine 3durvalumab 3Gemcitabine 3Cyclophosphamide 3Biopsy 3utomilumab 2ulixertinib 2pertuzumab 2osimertinib 2aldesleukin 2Trastuzumab 2Standard of Care 2Sirolimus 2Radiosurgery 2Psychiatric Rehabilitation 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Immunoglobulin G 2Docetaxel 2Disulfides 2Blood Specimen Collection 2zimberelimab 1vocimagene amiretrorepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Decitabine × Dermatologic × Clear all
NCT00030615 2013-02-07

Decitabine in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
BreastDermatologicGenitourinary

Urinary Bladder Neoplasms, Breast Neoplasms, Melanoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡